Search

Your search keyword '"Nielsen, S.M."' showing total 38 results
Start Over Author "Nielsen, S.M."
38 results on '"Nielsen, S.M."'

2. Germline Cancer Susceptibility in Individuals with Melanoma

Author

Funchain, P., primary, Ni, Y., additional, Heald, B., additional, Bungo, B., additional, Arbesman, M., additional, Behera, T.R., additional, McCormick, S., additional, Song, J.M., additional, Kennedy, L.B., additional, Nielsen, S.M., additional, Esplin, E.D., additional, Nizialek, E., additional, Ko, J., additional, Diaz-Montero, C.M., additional, Gastman, B., additional, Stratigos, A.J., additional, Artomov, M., additional, Tsao, H., additional, and Arbesman, J., additional

Published
2024
Full Text
View/download PDF

5. Biopsychosocial Rehabilitation for Inflammatory Arthritis and Osteoarthritis Patients: A systematic review and meta-analysis of randomized trials

Author

Pedersen, M.B., Thinggaard, P., Geenen, R., Rasmussen, M.U., De Wit, M., March, L., Mease, P., Choy, E., Conaghan, P.G., Simon, L., Hansen, A.F., Tarp, S., Schiøttz-Christensen, B., Juhl, C.B., Nielsen, S.M., Amris, K., Christensen, R., Pedersen, M.B., Thinggaard, P., Geenen, R., Rasmussen, M.U., De Wit, M., March, L., Mease, P., Choy, E., Conaghan, P.G., Simon, L., Hansen, A.F., Tarp, S., Schiøttz-Christensen, B., Juhl, C.B., Nielsen, S.M., Amris, K., and Christensen, R.

Abstract

Objective: To assess the benefits and harms associated with biopsychosocial rehabilitation in patients with inflammatory arthritis and osteoarthritis (OA). Methods: We performed a systematic review and meta-analysis. Data were collected through electronic searches of Cochrane CENTRAL, MEDLINE, Embase, PsycInfo, and CINAHL databases up to March 2019. Trials examining the effect of biopsychosocial rehabilitation in adults with inflammatory arthritis and/or OA were considered eligible, excluding rehabilitation adjunct to surgery. The primary outcome for benefit was pain and total withdrawals for harm. Results: Of the 27 trials meeting the eligibility criteria, 22 trials (3,750 participants) reported sufficient data to be included in the quantitative synthesis. For patient-reported outcome measures, biopsychosocial rehabilitation was slightly superior to control for pain relief (standardized mean difference [SMD] −0.19 [95% confidence interval (95% CI) −0.31, –0.07]), had a small effect on patient global assessment score (SMD –0.13 [95% CI –0.26, –0.00]), with no apparent effect on health-related quality of life, fatigue, self-reported disability/physical function, mental well-being, and reduction in pain intensity ≥30%. Clinician-measured outcomes displayed a small effect on observed disability/physical function (SMD −0.34 [95% CI −0.57, −0.10]), a large effect on physician global assessment score (SMD −0.72 [95% CI −1.18, −0.26]), and no effect on inflammation. No difference in harms existed in terms of the number of withdrawals, adverse events, or serious adverse events. Conclusion: Biopsychosocial rehabilitation produces a significant but clinically small beneficial effect on patient-reported pain among patients with inflammatory arthritis and OA, with no difference in harm. Methodologic weaknesses were observed in the included trials, suggesting low-to-moderate confidence in the estimates of effect.

Published
2023

6. Biopsychosocial Rehabilitation for Inflammatory Arthritis and Osteoarthritis Patients: A systematic review and meta-analysis of randomized trials

Author

Clinical Psychology (onderzoeksprogramma), Leerstoel Geenen, Pedersen, M.B., Thinggaard, P., Geenen, R., Rasmussen, M.U., De Wit, M., March, L., Mease, P., Choy, E., Conaghan, P.G., Simon, L., Hansen, A.F., Tarp, S., Schiøttz-Christensen, B., Juhl, C.B., Nielsen, S.M., Amris, K., Christensen, R., Clinical Psychology (onderzoeksprogramma), Leerstoel Geenen, Pedersen, M.B., Thinggaard, P., Geenen, R., Rasmussen, M.U., De Wit, M., March, L., Mease, P., Choy, E., Conaghan, P.G., Simon, L., Hansen, A.F., Tarp, S., Schiøttz-Christensen, B., Juhl, C.B., Nielsen, S.M., Amris, K., and Christensen, R.

Published
2023

7. Comparative Effectiveness Of Pharmacological Interventions For Hand Osteoarthritis: A Systematic Review And Network Meta-Analysis Of Randomized Trials

Author

Døssing, A., Nielsen, S.M., Kroon, F.p.b., Maria Balsby, I., Tarp, S., Kloppenburg, M., Stamp, L.k., Haugen, I.k., Altman, R.D., Henriksen, M., Boesen, M., Bliddal, H., Berg, S., Christensen, R., Døssing, A., Nielsen, S.M., Kroon, F.p.b., Maria Balsby, I., Tarp, S., Kloppenburg, M., Stamp, L.k., Haugen, I.k., Altman, R.D., Henriksen, M., Boesen, M., Bliddal, H., Berg, S., and Christensen, R.

Published
2023

8. Colchicine twice a day for hand osteoarthritis (COLOR)

Author

Dossing, A., Henriksen, M., Ellegaard, K., Nielsen, S.M., Stamp, L.K., Muller, F.C., Kloppenburg, M., Haugen, I.K., McCarthy, G.M., Conaghan, P.G., Dahl, L.U.M., Terslev, L., Altman, R.D., Becce, F., Ginnerup-Nielsen, E., Jensen, L., Boesen, M., Christensen, R., U. dal, and Bliddal, H.

Abstract

Background: Colchicine has been suggested for osteoarthritis treatment, but evidence is contradictory. We aimed to investigate colchicine's efficacy and safety compared with placebo in people with hand osteoarthritis. Methods: In this single-centre, double-blind, randomised, placebo-controlled trial we recruited adults with symptomatic hand osteoarthritis and finger pain of at least 40 mm on a 100 mm visual analogue scale from an outpatient clinic in Denmark. The hand with the most severe finger pain at inclusion was the target hand. Participants were randomly assigned (1:1) to 0 center dot 5 mg colchicine or placebo taken orally twice a day for 12 weeks, stratified by BMI (>= 30 kg/m2), sex, and age (>= 75 years). Participants, outcome assessors, and data analysts were masked to treatment allocation. The primary endpoint was change from baseline to week 12 in target hand finger pain, assessed on a 100 mm visual analogue scale with a pre-specified minimal clinically important difference of 15 mm, in the intention-to-treat population. Safety was assessed at week 12 in the intention-to-treat population. The study was registered with ClinicalTrials.gov, NCT04601883, and with EudraCT, 2020-002803-20. Findings: Between Jan 15, 2021, and March 3, 2022, 186 people were screened for eligibility, and 100 were randomly assigned to receive colchicine (n=50) or placebo (n=50). Participants had a mean age of 70 center dot 9 (SD 7 center dot 5) years, 69 (69%) of 100 were women and 31 (31%) were men. All participants completed the study. The mean change from baseline to week 12 in finger pain were -13 center dot 9 mm (SE 2 center dot 8) in the colchicine group and -13 center dot 5 mm (2 center dot 8) in the placebo group, with a between-group difference (colchicine vs placebo) of -0 center dot 4 mm (95% CI -7 center dot 6 to 6 center dot 7; p=0 center dot 90). In the colchicine group, there were 76 adverse events in 36 (72%) of 50 participants and one serious adverse advent (migraine attack leading to hospital admission). In the placebo group, there were 42 adverse events in 22 (44%) of 50 participants and two serious adverse events (cholecystitis and elevated alanine aminotransferase concentrations, in the same patient). Interpretation: In people with painful hand osteoarthritis, treatment with 0 center dot 5 mg of colchicine twice day for 12 weeks did not effectively relieve pain, and treatment with colchicine was associated with more adverse events.

Published
2023

9. Comparative Effectiveness Of Pharmacological Interventions For Hand Osteoarthritis: A Systematic Review And Network Meta-Analysis Of Randomized Trials

Author

Døssing, A., primary, Nielsen, S.M., additional, Kroon, F.P.B., additional, Maria Balsby, I., additional, Tarp, S., additional, Kloppenburg, M., additional, Stamp, L.K., additional, Haugen, I.K., additional, Altman, R.D., additional, Henriksen, M., additional, Boesen, M., additional, Bliddal, H., additional, Berg, S., additional, and Christensen, R., additional

Published
2023
Full Text
View/download PDF

11. Serum urate as a proposed surrogate outcome measure in gout trials: From the OMERACT working group

Author

Morillon M.B., Christensen R., Singh J.A., Dalbeth N., Saag K., Taylor W.J., Neogi T., Kennedy M.A., Pedersen B.M., McCarthy G.M., Shea B., Diaz-Torne C., Tedeschi S.K., Grainger R., Abhishek A., Gaffo A., Nielsen S.M., Noerup A., Simon L.S., Lassere M., Tugwell P., Stamp L.K., and Gout Working Group F.T.O.

Subjects
Patient Research Partners, Gout, Serum urate, Surrogate, OMERACT, Biomarker
Abstract

Serum urate (SU) is the most common primary efficacy outcome in trials of urate-lowering therapies for gout. Despite this, it is not formally considered a validated surrogate outcome. In this paper we will outline the definitions of biomarkers and surrogate outcome measures, respectively as well as the available frameworks and challenges in the assessment of the validity of serum urate as a surrogate in gout (i.e. a reasonable replacement for gout symptoms). © 2021 Elsevier Inc.

Published
2021

12. Cancer risks associated with germline PALB2 pathogenic variants: An international study of 524 families.

Author

Hake C., Redman J., Kleibl Z., Kleiblova P., Konstantopoulou I., Kvist A., Laduca H., Lee A.S.G., Lesueur F., Maher E.R., Mannermaa A., Manoukian S., McFarland R., McKinnon W., Meindl A., Metcalfe K., Taib N.A.M., Moilanen J., Nathanson K.L., Neuhausen S., Ng P.S., Nguyen-Dumont T., Nielsen S.M., Obermair F., Offit K., Olopade O.I., Ottini L., Penkert J., Pylkas K., Radice P., Ramus S.J., Rudaitis V., Side L., Silva-Smith R., Silvestri V., Skytte A.-B., Slavin T., Soukupova J., Tondini C., Trainer A.H., Unzeitig G., Usha L., Van Overeem Hansen T., Whitworth J., Wood M., Yip C.H., Yoon S.-Y., Yussuf A., Zogopoulos G., Goldgar D., Hopper J.L., Chenevix-Trench G., Pharoah P., George S.H.L., Balmana J., Houdayer C., James P., El-Haffaf Z., Ehrencrona H., Janatova M., Peterlongo P., Nevanlinna H., Schmutzler R., Teo S.-H., Robson M., Pal T., Couch F., Weitzel J.N., Elliott A., Southey M., Winqvist R., Easton D.F., Foulkes W.D., Antoniou A.C., Tischkowitz M., Yang X., Leslie G., Doroszuk A., Schneider S., Allen J., Decker B., Dunning A.M., Scarth J., Plaskocinska I., Luccarini C., Shah M., Pooley K., Dorling L., Leei A., Adank M.A., Adlard J., Aittomaki K., Andrulis I.L., Ang P., Barwell J., Bernstein J.L., Bobolis K., Borg A., Blomqvist C., Claes K.B.M., Concannon P., Cuggia A., Culver J.O., Damiola F., De Pauw A., Diez O., Dolinsky J.S., Domchek S.M., Engel C., Evans D.G., Fostira F., Garber J., Golmard L., Goode E.L., Gruber S.B., Hahnen E., Heikkinen T., Hurley J.E., Janavicius R., Hake C., Redman J., Kleibl Z., Kleiblova P., Konstantopoulou I., Kvist A., Laduca H., Lee A.S.G., Lesueur F., Maher E.R., Mannermaa A., Manoukian S., McFarland R., McKinnon W., Meindl A., Metcalfe K., Taib N.A.M., Moilanen J., Nathanson K.L., Neuhausen S., Ng P.S., Nguyen-Dumont T., Nielsen S.M., Obermair F., Offit K., Olopade O.I., Ottini L., Penkert J., Pylkas K., Radice P., Ramus S.J., Rudaitis V., Side L., Silva-Smith R., Silvestri V., Skytte A.-B., Slavin T., Soukupova J., Tondini C., Trainer A.H., Unzeitig G., Usha L., Van Overeem Hansen T., Whitworth J., Wood M., Yip C.H., Yoon S.-Y., Yussuf A., Zogopoulos G., Goldgar D., Hopper J.L., Chenevix-Trench G., Pharoah P., George S.H.L., Balmana J., Houdayer C., James P., El-Haffaf Z., Ehrencrona H., Janatova M., Peterlongo P., Nevanlinna H., Schmutzler R., Teo S.-H., Robson M., Pal T., Couch F., Weitzel J.N., Elliott A., Southey M., Winqvist R., Easton D.F., Foulkes W.D., Antoniou A.C., Tischkowitz M., Yang X., Leslie G., Doroszuk A., Schneider S., Allen J., Decker B., Dunning A.M., Scarth J., Plaskocinska I., Luccarini C., Shah M., Pooley K., Dorling L., Leei A., Adank M.A., Adlard J., Aittomaki K., Andrulis I.L., Ang P., Barwell J., Bernstein J.L., Bobolis K., Borg A., Blomqvist C., Claes K.B.M., Concannon P., Cuggia A., Culver J.O., Damiola F., De Pauw A., Diez O., Dolinsky J.S., Domchek S.M., Engel C., Evans D.G., Fostira F., Garber J., Golmard L., Goode E.L., Gruber S.B., Hahnen E., Heikkinen T., Hurley J.E., and Janavicius R.

Abstract

PURPOSE To estimate age-specific relative and absolute cancer risks of breast cancer and to estimate risks of ovarian, pancreatic, male breast, prostate, and colorectal cancers associated with germline PALB2 pathogenic variants (PVs) because these risks have not been extensively characterized. METHODS We analyzed data from 524 families with PALB2 PVs from 21 countries. Complex segregation analysis was used to estimate relative risks (RRs; relative to country-specific population incidences) and absolute risks of cancers. The models allowed for residual familial aggregation of breast and ovarian cancer and were adjusted for the family-specific ascertainment schemes. RESULTS We found associations between PALB2 PVs and risk of female breast cancer (RR, 7.18; 95% CI, 5.82 to 8.85; P = 6.5 x 10-76), ovarian cancer (RR, 2.91; 95% CI, 1.40 to 6.04; P = 4.1 x 10-3), pancreatic cancer (RR, 2.37; 95% CI, 1.24 to 4.50; P = 8.7 x 10-3), and male breast cancer (RR, 7.34; 95% CI, 1.28 to 42.18; P = 2.6 3 1022). There was no evidence for increased risks of prostate or colorectal cancer. The breast cancer RRs declined with age (P for trend = 2.0 x 10-3). After adjusting for family ascertainment, breast cancer risk estimates on the basis of multiple case families were similar to the estimates from families ascertained through population-based studies (P for difference = .41). On the basis of the combined data, the estimated risks to age 80 years were 53% (95% CI, 44% to 63%) for female breast cancer, 5% (95% CI, 2% to 10%) for ovarian cancer, 2%-3% (95% CI females, 1% to 4%; 95% CI males, 2% to 5%) for pancreatic cancer, and 1% (95% CI, 0.2% to 5%) for male breast cancer. CONCLUSION These results confirm PALB2 as a major breast cancer susceptibility gene and establish substantial associations between germline PALB2 PVs and ovarian, pancreatic, and male breast cancers. These findings will facilitate incorporation of PALB2 into risk prediction models and optimize the clinical cancer ri

Published
2020

15. Identifying Provisional Generic Contextual Factor Domains for Clinical Trials in Rheumatology: Results from an OMERACT Initiative

Author

Nielsen, S.M., Tugwell, P., Wit, M.P.T. de, Boers, M., Beaton, D.E., Woodworth, T.G., Escorpizo, R., Shea, B., Toupin-April, K., Guillemin, F., Strand, V., Singh, J.A., Kloppenburg, M., Furst, D.E., Wells, G.A., Smolen, J.S., Vesely, R., Boonen, A., Storgaard, H., Voshaar, M., March, L., Christensen, R., Contextual Factors Working Grp, University of Ottawa [Ottawa] (uOttawa), Department of Clinical Epidemiology and Biostatistics, VU University Medical Center [Amsterdam], Institute for Work and Health (IWH), University of Toronto-St. Michael's Hospital-Institute of Medical Sciences, University of California [Los Angeles] (UCLA), University of California, Maladies chroniques, santé perçue, et processus d'adaptation (APEMAC), Université de Lorraine (UL), Stanford University School of Medicine [Stanford], Stanford University [Stanford], Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Maastricht University Medical Center (MUMC), Maastricht University [Maastricht], Institute of Bone & Joint Research, Royal North Shore Hospital (RNSH)-The University of Sydney, The Parker Institute, University of Copenhagen = Københavns Universitet (KU), Interne Geneeskunde, MUMC+: MA Reumatologie (9), RS: CAPHRI - R3 - Functioning, Participating and Rehabilitation, Ethics, Law & Medical humanities, APH - Methodology, Epidemiology and Data Science, University of Ottawa [Ottawa], Stanford School of Medicine [Stanford], Stanford Medicine, Stanford University-Stanford University, Maastricht University Medical Centre (MUMC), and Psychology, Health & Technology

Subjects
RHEUMATIC DISEASES, medicine.medical_specialty, Consensus, Immunology, Applied psychology, Session (web analytics), 03 medical and health sciences, 0302 clinical medicine, Rheumatology, Risk Factors, Internal medicine, Outcome Assessment, Health Care, Humans, Immunology and Allergy, Medicine, 030212 general & internal medicine, ComputingMilieux_MISCELLANEOUS, 030203 arthritis & rheumatology, OUTCOMES, business.industry, OMERACT, Special Interest Group, Prognosis, n/a OA procedure, Clinical trial, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, business, CLINICAL TRIALS, Healthcare system
Abstract

Objective.The Contextual Factors Working Group aims to provide guidance on addressing contextual factors in rheumatology trials within OMERACT.Methods.During the Special Interest Group session at OMERACT 2018, preliminary results were presented from a case scenario survey and semistructured interviews, including contextual factors mentioned in these. A group-based exercise sought to identify and rank important generic contextual factors.Results.A total of 79 candidate factors were listed. Across the 3 groups, gender/sex, comorbidities, and the healthcare system were ranked as most important.Conclusion.The identified important contextual factor domains may be considered a provisional list pending further research.

Published
2019
Full Text
View/download PDF

16. Inter‐rater reliability and agreement hidradenitis suppurativa instruments

Author

Thorlacius, L., primary, Garg, A., additional, Riis, P.T., additional, Nielsen, S.M., additional, Bettoli, V., additional, Ingram, J.R., additional, Marmol, V., additional, Matusiak, L., additional, Pascual, J.C., additional, Revuz, J., additional, Sartorius, K., additional, Tzellos, T., additional, Zee, H.H., additional, Zouboulis, C.C., additional, Saunte, D.M., additional, Gottlieb, A.B., additional, Christensen, R., additional, and Jemec, G.B.E., additional

Published
2019
Full Text
View/download PDF

17. 化脓性汗腺炎量表的评定者间可靠性和一致性

Author

Thorlacius, L., primary, Garg, A., additional, Riis, P.T., additional, Nielsen, S.M., additional, Bettoli, V., additional, Ingram, J.R., additional, Marmol, V., additional, Matusiak, L., additional, Pascual, J.C., additional, Revuz, J., additional, Sartorius, K., additional, Tzellos, T., additional, Zee, H.H., additional, Zouboulis, C.C., additional, Saunte, D.M., additional, Gottlieb, A.B., additional, Christensen, R., additional, and Jemec, G.B.E., additional

Published
2019
Full Text
View/download PDF

18. Inter‐rater agreement and reliability of outcome measurement instruments and staging systems used in hidradenitis suppurativa

Author

Thorlacius, L., primary, Garg, A., additional, Riis, P.T., additional, Nielsen, S.M., additional, Bettoli, V., additional, Ingram, J.R., additional, Marmol, V., additional, Matusiak, L., additional, Pascual, J.C., additional, Revuz, J., additional, Sartorius, K., additional, Tzellos, T., additional, Zee, H.H., additional, Zouboulis, C.C., additional, Saunte, D.M., additional, Gottlieb, A.B., additional, Christensen, R., additional, and Jemec, G.B.E., additional

Published
2019
Full Text
View/download PDF

19. Role of genetic testing for inherited prostate cancer risk: Philadelphia prostate cancer consensus conference 2017

Author

Giri, V.N. (Veda), Knudsen, K.E. (Karen E.), Kelly, W.K. (William K.), Abida, W. (Wassim), Andriole, G.L. (Gerald), Bangma, C.H. (Chris), Bekelman, J.E. (Justin E.), Benson, M.C. (Mitchell C.), Blanco, A. (Amie), Burnett, A. (Arthur), Catalona, W.J. (William J.), Cooney, K.A. (Kathleen A.), Cooperberg, M.R. (Matthew), Crawford, D. (David), Den, R.B. (Robert B.), Dicker, A.P. (Adam P.), Eggener, S. (Scott), Fleshner, N.E. (Neil), Freedman, M.L. (Matthew L.), Hamdy, F. (Freddie), Hoffman-Censits, J. (Jean), Hurwitz, M.D. (Mark D.), Hyatt, C. (Colette), Isaacs, W.B. (William B.), Kane, C.J. (Christopher J.), Kantoff, P. (Philip), Karnes, R.J. (Jeffrey), Karsh, L.I. (Lawrence I.), Klein, E.A. (Eric A.), Lin, D.W. (Daniel W.), Loughlin, K.R. (Kevin R.), Lu-Yao, G. (Grace), Malkowicz, S.B. (S. Bruce), Mann, M.J. (Mark J.), Mark, J.R. (James R.), McCue, P.A. (Peter A.), Miner, M.M. (Martin M.), Morgan, T. (Todd), Moul, J.W. (Judd W.), Myers, R.E. (Ronald E.), Nielsen, S.M. (Sarah M.), Obeid, E. (Elias), Pavlovich, C.P. (Christian P.), Peiper, S.C. (Stephen C.), Penson, D.F. (David F.), Petrylak, D.P. (Daniel P), Pettaway, C.A. (Curtis A.), Pilarski, R. (Robert), Pinto, P. (Peter), Poage, W. (Wendy), Raj, G.V. (Ganesh V.), Rebbeck, R. (Timothy), Robson, M. (Mark), Rosenberg, M.T. (Matt T.), Sandler, H. (Howard), Sartor, A.O. (Oliver), Schaeffer, E. (Edward), Schwartz, G.F. (Gordon F.), Shahin, M.S. (Mark S.), Shore, N.D. (Neal), Shuch, B. (Brian), Soule, H.R. (Howard R.), Tomlins, S.A. (Scott A), Trabulsi, E.J. (Edouard J.), Uzzo, R. (Robert), Griend, D.J.V. (Donald J. Vander), Walsh, P.C. (Patrick), Weil, C.J. (Carol J.), Wender, R. (Richard), Gomella, L.G. (Leonard G.), Giri, V.N. (Veda), Knudsen, K.E. (Karen E.), Kelly, W.K. (William K.), Abida, W. (Wassim), Andriole, G.L. (Gerald), Bangma, C.H. (Chris), Bekelman, J.E. (Justin E.), Benson, M.C. (Mitchell C.), Blanco, A. (Amie), Burnett, A. (Arthur), Catalona, W.J. (William J.), Cooney, K.A. (Kathleen A.), Cooperberg, M.R. (Matthew), Crawford, D. (David), Den, R.B. (Robert B.), Dicker, A.P. (Adam P.), Eggener, S. (Scott), Fleshner, N.E. (Neil), Freedman, M.L. (Matthew L.), Hamdy, F. (Freddie), Hoffman-Censits, J. (Jean), Hurwitz, M.D. (Mark D.), Hyatt, C. (Colette), Isaacs, W.B. (William B.), Kane, C.J. (Christopher J.), Kantoff, P. (Philip), Karnes, R.J. (Jeffrey), Karsh, L.I. (Lawrence I.), Klein, E.A. (Eric A.), Lin, D.W. (Daniel W.), Loughlin, K.R. (Kevin R.), Lu-Yao, G. (Grace), Malkowicz, S.B. (S. Bruce), Mann, M.J. (Mark J.), Mark, J.R. (James R.), McCue, P.A. (Peter A.), Miner, M.M. (Martin M.), Morgan, T. (Todd), Moul, J.W. (Judd W.), Myers, R.E. (Ronald E.), Nielsen, S.M. (Sarah M.), Obeid, E. (Elias), Pavlovich, C.P. (Christian P.), Peiper, S.C. (Stephen C.), Penson, D.F. (David F.), Petrylak, D.P. (Daniel P), Pettaway, C.A. (Curtis A.), Pilarski, R. (Robert), Pinto, P. (Peter), Poage, W. (Wendy), Raj, G.V. (Ganesh V.), Rebbeck, R. (Timothy), Robson, M. (Mark), Rosenberg, M.T. (Matt T.), Sandler, H. (Howard), Sartor, A.O. (Oliver), Schaeffer, E. (Edward), Schwartz, G.F. (Gordon F.), Shahin, M.S. (Mark S.), Shore, N.D. (Neal), Shuch, B. (Brian), Soule, H.R. (Howard R.), Tomlins, S.A. (Scott A), Trabulsi, E.J. (Edouard J.), Uzzo, R. (Robert), Griend, D.J.V. (Donald J. Vander), Walsh, P.C. (Patrick), Weil, C.J. (Carol J.), Wender, R. (Richard), and Gomella, L.G. (Leonard G.)

Abstract

Purpose: Guidelines are limited for genetic testing for prostate cancer (PCA). The goal of this conference was to develop an expert consensus-driv

Published
2018
Full Text
View/download PDF

20. OP0018 The value of adding mri to a clinical treat-to-target strategy in rheumatoid arthritis patients in clinical remission: clinical and radiographic outcomes from the imagine-ra randomised controlled trial

Author

Møller-bisgaard, S., Hørslev-pedersen, K., Ejbjerg, B., Hetland, M., Ørnbjerg, L., Glinatsi, D., Møller, J., Boesen, M., Christensen, R., Stengaard-pedersen, K., Madsen, O.r., Jensen, B., Villadsen, J., Hauge, E.-m., Bennett, P., Hendricks, O., Asmussen, K., Kowalski, M., Lindegaard, H., Nielsen, S.m., Bliddal, H., Krogh, N., Ellingsen, T., Nielsen, A.h., Balding, L., Jurik, A.g., Thomsen, H., Østergaard, M., Møller-bisgaard, S., Hørslev-pedersen, K., Ejbjerg, B., Hetland, M., Ørnbjerg, L., Glinatsi, D., Møller, J., Boesen, M., Christensen, R., Stengaard-pedersen, K., Madsen, O.r., Jensen, B., Villadsen, J., Hauge, E.-m., Bennett, P., Hendricks, O., Asmussen, K., Kowalski, M., Lindegaard, H., Nielsen, S.m., Bliddal, H., Krogh, N., Ellingsen, T., Nielsen, A.h., Balding, L., Jurik, A.g., Thomsen, H., and Østergaard, M.

Published
2018

21. Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores

Author

Lecarpentier, J., Silvestri, V., Kuchenbaecker, K.B., Barrowdale, D., Dennis, J., McGuffog, L., Soucy, P., Leslie, G., Rizzolo, P., Navazio, A.S., Valentini, V., Zelli, V., Lee, A., Olama, A.A. al, Tyrer, J.P., Southey, M., John, E.M., Conner, T.A., Goldgar, D.E., Buys, S.S., Janavicius, R., Steele, L., Ding, Y.C., Neuhausen, S.L., Hansen, T.V.O., Osorio, A., Weitzel, J.N., Toss, A., Medici, V., Cortesi, L., Zanna, I., Palli, D., Radice, P., Manoukian, S., Peissel, B., Azzollini, J., Viel, A., Cini, G., Damante, G., Tommasi, S., Peterlongo, P., Fostira, F., Hamann, U., Evans, D.G., Henderson, A., Brewer, C., Eccles, D., Cook, J., Ong, K.R., Walker, L., Side, L.E., Porteous, M.E., Davidson, R., Hodgson, S., Frost, D., Adlard, J., Izatt, L., Eeles, R., Ellis, S., Tischkowitz, M., Godwin, A.K., Meindl, A., Gehrig, A., Dworniczak, B., Sutter, C., Engel, C., Niederacher, D., Steinemann, D., Hahnen, E., Hauke, J., Rhiem, K., Kast, K., Arnold, N., Ditsch, N., Wang-Gohrke, S., Wappenschmidt, B., Wand, D., Lasset, C., Stoppa-Lyonnet, D., Belotti, M., Damiola, F., Barjhoux, L., Mazoyer, S., Heetvelde, M. van, Poppe, B., Leeneer, K. de, Claes, K.B.M., Hoya, M. de la, Garcia-Barberan, V., Caldes, T., Perez Segura, P., Kiiski, J.I., Aittomaki, K., Khan, S., Nevanlinna, H., Asperen, C.J. van, Vaszko, T., Kasler, M., Olah, E., Balmana, J., Gutierrez-Enriquez, S., Diez, O., Teule, A., Izquierdo, A., Darder, E., Brunet, J., Valle, J. del, Feliubadalo, L., Pujana, M.A., Lazaro, C., Arason, A., Agnarsson, B.A., Johannsson, O.T., Barkardottir, R.B., Alducci, E., Tognazzo, S., Montagna, M., Teixeira, M.R., Pinto, P., Spurdle, A.B., Holland, H., Lee, J.W., Lee, M.H., Lee, J., Kim, S.W., Kang, E., Kim, Z., Sharma, P., Rebbeck, T.R., Vijai, J., Robson, M., Lincoln, A., Musinsky, J., Gaddam, P., Tan, Y.Y., Berger, A., Singer, C.F., Loud, J.T., Greene, M.H., Mulligan, A.M., Glendon, G., Andrulis, I.L., Toland, A.E., Senter, L., Bojesen, A., Nielsen, H.R., Skytte, A.B., Sunde, L., Jensen, U.B., Pedersen, I.S., Krogh, L., Kruse, T.A., Caligo, M.A., Yoon, S.Y., Teo, S.H., Wachenfeldt, A. von, Huo, D., Nielsen, S.M., Olopade, O.I., Nathanson, K.L., Domchek, S.M., Lorenchick, C., Jankowitz, R.C., Campbell, I., James, P., Mitchell, G., Orr, N., Park, S.K., Thomassen, M., Offit, K., Couch, F.J., Simard, J., Easton, D.F., Chenevix-Trench, G., Schmutzler, R.K., Antoniou, A.C., Ottini, L., EMBRACE, GEMO Study Collaborators, HEBON, KConFab Investigators, Dennis, Joe [0000-0003-4591-1214], Leslie, Goska [0000-0001-5756-6222], Lee, Andrew [0000-0003-0677-0252], Amin Al Olama, Ali [0000-0002-7178-3431], Tyrer, Jonathan [0000-0003-3724-4757], Tischkowitz, Marc [0000-0002-7880-0628], Easton, Douglas [0000-0003-2444-3247], Antoniou, Antonis [0000-0001-9223-3116], and Apollo - University of Cambridge Repository

Subjects
Adult, Aged, 80 and over, Male, Heterozygote, Multifactorial Inheritance, Genes, BRCA2, Age Factors, Genes, BRCA1, Prostatic Neoplasms, Middle Aged, Polymorphism, Single Nucleotide, Risk Assessment, Breast Neoplasms, Male, Case-Control Studies, Mutation, Humans, Genetic Predisposition to Disease, Genetic Testing, skin and connective tissue diseases, Aged, Genome-Wide Association Study
Abstract

$\textbf{Purpose}$ $\textit{BRCA1/2}$ mutations increase the risk of breast and prostate cancer in men. Common genetic variants modify cancer risks for female carriers of $\textit{BRCA1/2}$ mutations. We investigated-for the first time to our knowledge-associations of common genetic variants with breast and prostate cancer risks for male carriers of $\textit{BRCA1/2}$ mutations and implications for cancer risk prediction. $\textbf{Materials and Methods}$ We genotyped 1,802 male carriers of $\textit{BRCA1/2}$ mutations from the Consortium of Investigators of Modifiers of $\textit{BRCA1/2}$ by using the custom Illumina OncoArray. We investigated the combined effects of established breast and prostate cancer susceptibility variants on cancer risks for male carriers of $\textit{BRCA1/2}$ mutations by constructing weighted polygenic risk scores (PRSs) using published effect estimates as weights. $\textbf{Results}$ In male carriers of $\textit{BRCA1/2}$ mutations, PRS that was based on 88 female breast cancer susceptibility variants was associated with breast cancer risk (odds ratio per standard deviation of PRS, 1.36; 95% CI, 1.19 to 1.56; $P$ = 8.6 × 10$^{-6}$)). Similarly, PRS that was based on 103 prostate cancer susceptibility variants was associated with prostate cancer risk (odds ratio per SD of PRS, 1.56; 95% CI, 1.35 to 1.81; $P$ = 3.2 × 10$^{-9}$)). Large differences in absolute cancer risks were observed at the extremes of the PRS distribution. For example, prostate cancer risk by age 80 years at the 5th and 95th percentiles of the PRS varies from 7% to 26% for carriers of $\textit{BRCA1}$ mutations and from 19% to 61% for carriers of $\textit{BRCA2}$ mutations, respectively. $\textbf{Conclusion}$ PRSs may provide informative cancer risk stratification for male carriers of $\textit{BRCA1/2}$ mutations that might enable these men and their physicians to make informed decisions on the type and timing of breast and prostate cancer risk management.

Published
2017

23. OP0149 An mri guided treat-to-target strategy in rheumatoid arthritis patients in clinical remission improved mri inflammation but not damage progression – results from the imagine-ra randomised controlled trial

Author

Møller-Bisgaard, S., primary, Hørslev-Pedersen, K., additional, Ejbjerg, B., additional, Glinatsi, D., additional, Hetland, M., additional, Ørnbjerg, L., additional, Møller, J., additional, Boesen, M., additional, Christensen, R., additional, Stengaard-Pedersen, K., additional, Madsen, O.R., additional, Jensen, B., additional, Villadsen, J., additional, Hauge, E.-M., additional, Bennett, P., additional, Hendricks, O., additional, Asmussen, K., additional, Kowalski, M., additional, Lindegaard, H., additional, Nielsen, S.M., additional, Bliddal, H., additional, Krogh, N., additional, Ellingsen, T., additional, Nielsen, A.H., additional, Balding, L., additional, Jurik, A.G., additional, Thomsen, H., additional, and Østergaard, M., additional

Published
2018
Full Text
View/download PDF

24. OP0219-HPR The efficacy of motivational counselling and sms-reminders on daily sitting time in patients with rheumatoid arthritis: 22 months follow-up of a randomised, parallel-group trial

Author

Thomsen, T., primary, Aadahl, M., additional, Beyer, N., additional, Hetland, M.L., additional, Løppenthin, K.B., additional, Midtgaard, J., additional, Christensen, R., additional, Nielsen, S.M., additional, Østergaard, M., additional, Jennum, P., additional, and Esbensen, B.A., additional

Published
2018
Full Text
View/download PDF

25. OP0018 The value of adding mri to a clinical treat-to-target strategy in rheumatoid arthritis patients in clinical remission: clinical and radiographic outcomes from the imagine-ra randomised controlled trial

Author

Møller-Bisgaard, S., primary, Hørslev-Pedersen, K., additional, Ejbjerg, B., additional, Hetland, M., additional, Ørnbjerg, L., additional, Glinatsi, D., additional, Møller, J., additional, Boesen, M., additional, Christensen, R., additional, Stengaard-Pedersen, K., additional, Madsen, O.R., additional, Jensen, B., additional, Villadsen, J., additional, Hauge, E.-M., additional, Bennett, P., additional, Hendricks, O., additional, Asmussen, K., additional, Kowalski, M., additional, Lindegaard, H., additional, Nielsen, S.M., additional, Bliddal, H., additional, Krogh, N., additional, Ellingsen, T., additional, Nielsen, A.H., additional, Balding, L., additional, Jurik, A.G., additional, Thomsen, H., additional, and Østergaard, M., additional

Published
2018
Full Text
View/download PDF

26. SAT0303 Pain mechanisms and ultrasonic inflammatory activity as prognostic factors in patients with psoriatic arthritis: results of a danish prospective, exploratory cohort study

Author

Højgaard, P., primary, Ellegaard, K., additional, Nielsen, S.M., additional, Christensen, R., additional, Guldberg-Møller, J., additional, Ballegaard, C., additional, Dreyer, L., additional, Mease, P., additional, de Wit, M., additional, Skov, L., additional, Glintborg, B., additional, Bliddal, H., additional, Bartels, E.M., additional, Amris, K., additional, and Kristensen, L.E., additional

Published
2018
Full Text
View/download PDF

32. Etiology of common childhood acute lymphoblastic leukemia: the adrenal hypothesis

Author

Schmiegelow, K., Vestergaard, T., Nielsen, S.M., Hjalgrim, H., Schmiegelow, K., Vestergaard, T., Nielsen, S.M., and Hjalgrim, H.

Abstract

The pattern of infections in the first years of life modulates our immune system, and a low incidence of infections has been linked to an increased risk of common childhood acute lymphoblastic leukemia (ALL). We here present a new interpretation of these observations--the adrenal hypothesis--that proposes that the risk of childhood ALL is reduced when early childhood infections induce qualitative and quantitative changes in the hypothalamus-pituitary-adrenal axis that increase plasma cortisol levels. This may directly eliminate leukemic cells as well as preleukemic cells for the ALL subsets that dominate in the first 5-7 years of life and may furthermore suppress the Th1-dominated proinflammatory response to infections, and thus lower the proliferative stress on pre-existing preleukemic cells Udgivelsesdato: 2008/12

Published
2008

Catalog

Books, media, physical & digital resources
See catalog results